Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications
Controlled trialHumansTopical
- Design
- Controlled trial
- Subjects
- 30 glaucoma patients on hypotensive eye drops: 15 added topical PEA, 15 had no added treatment
- Dose used in the study
- Topical PEA eye preparation (Defluxa) added to the patient's glaucoma drops; concentration not stated in the abstract
- Duration
- 30 days, assessed at days 0, 15 and 30
- What was measured
- Schirmer tear test, tear film break-up time, conjunctival redness, visual acuity, intraocular pressure, adverse events
What the authors reported
In the PEA group, Schirmer test (p < 0.05), tear break-up time (p < 0.0001) and conjunctival redness (p < 0.0001) improved from baseline by day 30. Against the untreated group, redness was lower by day 15 and the two tear measures better by day 30.
Limits of this study
Pilot of 15 per group. The control group received no added treatment and no placebo drops, so the comparison is unblinded. Allocation method not stated in the abstract. A branded eye product.
Source
PubMed 29045169 · doi:10.1089/jop.2016.0117
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.